374 related articles for article (PubMed ID: 30715612)
1. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kerr D; Zhang L; Sokol L
Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
[TBL] [Abstract][Full Text] [Related]
2. The advances in therapy of blastic plasmacytoid dendritic cell neoplasm.
Kerr D; Sokol L
Expert Opin Investig Drugs; 2018 Sep; 27(9):733-739. PubMed ID: 30118336
[TBL] [Abstract][Full Text] [Related]
3. Blastic Plasmacytoid Dendritic Cell Neoplasm.
Jain A; Sweet K
J Natl Compr Canc Netw; 2023 May; 21(5):515-521. PubMed ID: 37156483
[TBL] [Abstract][Full Text] [Related]
4. Blastic plasmacytoid dendritic cell neoplasm: update on molecular biology, diagnosis, and therapy.
Riaz W; Zhang L; Horna P; Sokol L
Cancer Control; 2014 Oct; 21(4):279-89. PubMed ID: 25310209
[TBL] [Abstract][Full Text] [Related]
5. CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
Pemmaraju N; Wilson NR; Senapati J; Economides MP; Guzman ML; Neelapu SS; Kazemimood R; Davis RE; Jain N; Khoury JD; Sugita M; Cai T; Smith J; Frattini MG; Garton A; Roboz G; Konopleva M
Leuk Res; 2022 Oct; 121():106928. PubMed ID: 35963025
[TBL] [Abstract][Full Text] [Related]
6. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
[TBL] [Abstract][Full Text] [Related]
7. A critical review of treatment modalities for blastic plasmacytoid dendritic cell neoplasm.
Falcone U; Sibai H; Deotare U
Crit Rev Oncol Hematol; 2016 Nov; 107():156-162. PubMed ID: 27823644
[TBL] [Abstract][Full Text] [Related]
8. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
Economides MP; Rizzieri D; Pemmaraju N
Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
[TBL] [Abstract][Full Text] [Related]
9. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
[TBL] [Abstract][Full Text] [Related]
10. A Very Rare Type of Leukemia in a Young Pediatric Patient Treated With Hematopoietic Stem Cell Transplantation: Blastic Plasmacytoid Dendritic Cell Neoplasm.
Tekkeşin F; Asarcikli F; Yildirim ÜM; Zemheri IE; Kiliç SÇ
J Pediatr Hematol Oncol; 2021 Mar; 43(2):e288-e291. PubMed ID: 33235146
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapies Targeting CD123 for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Xue T; Budde LE
Hematol Oncol Clin North Am; 2020 Jun; 34(3):575-587. PubMed ID: 32336421
[TBL] [Abstract][Full Text] [Related]
12. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
Zanotta S; Galati D; De Filippi R; Pinto A
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
[TBL] [Abstract][Full Text] [Related]
13. A Case of Cutaneous Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With a Bcl-2 Inhibitor.
Egger A; Coello D; Kirsner RS; Brehm JE
J Drugs Dermatol; 2021 May; 20(5):550-551. PubMed ID: 33938687
[TBL] [Abstract][Full Text] [Related]
14. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
[TBL] [Abstract][Full Text] [Related]
15. Hematopoietic Cell Transplant for Blastic Plasmacytoid Dendritic Cell Neoplasm.
Kharfan-Dabaja MA; Cherry M
Hematol Oncol Clin North Am; 2020 Jun; 34(3):621-629. PubMed ID: 32336425
[TBL] [Abstract][Full Text] [Related]
16. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
Adimora IJ; Wilson NR; Pemmaraju N
Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
[TBL] [Abstract][Full Text] [Related]
17. Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.
Lee SS; McCue D; Pemmaraju N
Expert Rev Anticancer Ther; 2020 Jul; 20(7):543-550. PubMed ID: 32460559
[TBL] [Abstract][Full Text] [Related]
18. Evaluating tagraxofusp for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
Wilson NR; Pemmaraju N
Expert Opin Pharmacother; 2022 Mar; 23(4):431-438. PubMed ID: 35060807
[TBL] [Abstract][Full Text] [Related]
19. Pediatric blastic plasmacytoid dendritic cell neoplasm: report of four cases and review of literature.
Liao C; Hu NX; Song H; Zhang JY; Shen DY; Xu XJ; Tang YM
Int J Hematol; 2021 May; 113(5):751-759. PubMed ID: 33392975
[TBL] [Abstract][Full Text] [Related]
20. Tagraxofusp, the first CD123-targeted therapy and first targeted treatment for blastic plasmacytoid dendritic cell neoplasm.
Economides MP; McCue D; Lane AA; Pemmaraju N
Expert Rev Clin Pharmacol; 2019 Oct; 12(10):941-946. PubMed ID: 31465247
[No Abstract] [Full Text] [Related]
[Next] [New Search]
